In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid

2017 ◽  
Vol 25 (1) ◽  
pp. 409-419 ◽  
Author(s):  
Isao Shibuya ◽  
Masamichi Takami ◽  
Arei Miyamoto ◽  
Akiko Karakawa ◽  
Akira Dezawa ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
In Vitro Study ◽  
Cell Tumor ◽  
Vitro Study

Giant Cell Tumor of Bone: A Model for the in Vitro Human Osteoclast Characterization

1989 ◽  
Vol 75 (4) ◽  
pp. 389-395 ◽  
Author(s):  
Mario Campanacci ◽  
Gian Paolo Bagnara ◽  
Massimo Serra ◽  
Marco Giovannini ◽  
Paolo Tornasi ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Giant Cells ◽  
Cell Tumor ◽  
Cell Populations ◽  
In Vitro Growth ◽  
Human Osteoclast ◽  
High Doses

The in vitro growth pattern of cells obtained from bioptic material of ten patients with giant cell tumor of bone (GCT) was investigated. Cytochemical reactions and monoclonal antibodies raised against macrophage markers were tested on the two histologically identifiable GCT cell populations. Only monoclonal antibody EBM/11 stained both mononuclear and giant cells. EBM/11 positivity and resistance of acid phosphatase to high doses of tartrate strongly suggest that both mononuclear and giant cells belong to the same lineage.

scholarly journals The Role of TWIST in Angiogenesis and Cell Migration in Giant Cell Tumor of Bone

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Shalini Singh ◽  
Isabella W. Y. Mak ◽  
Divya Handa ◽  
Michelle Ghert
Keyword(s):  
Cell Migration ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Stromal Cells ◽  
Epithelial Mesenchymal Transition ◽  
Cell Tumor ◽  
Stable Cell Line ◽  
Mesenchymal Transition

Giant cell tumor of bone (GCT) is a bone tumor consisting of numerous multinucleated osteoclastic giant cells involved in bone resorption and neoplastic osteoblast-like stromal cells responsible for tumor growth. The tumor occasionally metastasizes to the lung; however, factors leading to metastasis in this tumor are unknown. The TWIST-1 protein (also referred to as TWIST) has been suggested to be involved in epithelial-mesenchymal transition (EMT) and tumor progression in some cancers. In this study we investigated the functional role of TWIST in GCT cell angiogenesis and migration. Overexpression of TWIST in neoplastic GCT stromal cells significantly increased mRNA and protein expression of VEGF and VEGFR1 in vitro, whereas knockdown of TWIST resulted in decreased VEGF and VEGFR1 expression. A stable cell line with TWIST overexpression resulted in features of EMT including increased cell migration and downregulation of E-cadherin. The results of our study indicate that TWIST may play an important role in angiogenesis and cell migration in GCT.

Zoledronic acid-loaded bone cement as a local adjuvant therapy for giant cell tumor of the sacrum after intralesional curettage

2015 ◽  
Vol 24 (10) ◽  
pp. 2182-2188 ◽  
Author(s):  
Kun-Hui Chen ◽  
Po-Kuei Wu ◽  
Cheng-Fong Chen ◽  
Wei-Ming Chen
Keyword(s):  
Zoledronic Acid ◽  
Adjuvant Therapy ◽  
Bone Cement ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Cell Tumor ◽  
Intralesional Curettage

scholarly journals Combination of Melatonin and Zoledronic Acid Suppressed the Giant Cell Tumor of Bone in vitro and in vivo

2021 ◽  
Vol 9 ◽  
Author(s):  
Xudong Wang ◽  
Peiqiang Su ◽  
Yan Kang ◽  
Caixia Xu ◽  
Jincheng Qiu ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Osteogenic Differentiation ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Therapeutic Effect ◽  
Antitumor Effect ◽  
Cell Tumor ◽  
Cell Counting ◽  
Migration And Invasion ◽  
Antitumor Effects

Melatonin (Mlt) confers potential antitumor effects in various types of cancer. However, to the best of our knowledge, the role of Mlt in the giant cell tumor of bone (GCTB) remains unknown. Moreover, further research is required to assess whether Mlt can enhance the therapeutic effect of zoledronic acid (Zol), a commonly used anti-GCTB drug. In this research, we investigated the effects of Mlt, Zol, and the combination of these two drugs on GCTB cells’ characteristics, including cell proliferation, apoptosis, osteogenic differentiation, migration, and invasion. The cell counting kit-8 (CCK-8) assay, colony formation assay, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay (TUNEL), alkaline phosphatase (ALP) staining, alizarin red staining (ARS), scratch wound healing assay, and transwell experiment were performed, respectively. Our results showed that Mlt could effectively inhibit the proliferation, migration, and invasion of GCTB cells, as well as promote the apoptosis and osteogenic differentiation of tumor cells. Of note, a stronger antitumor effect was observed when Mlt was combined with Zol treatment. This therapeutic effect might be achieved by inhibiting the activation of both the Hippo and NF-κB pathways. In conclusion, our study suggests that Mlt can be a new treatment for GCTB, which could further enhance the antitumor effect of Zol.

Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone

2013 ◽  
Vol 54 (6) ◽  
pp. 439-449 ◽  
Author(s):  
Carol P. Y. Lau ◽  
Lin Huang ◽  
Kwok Chuen Wong ◽  
Shekhar Madhukar Kumta
Keyword(s):  
Zoledronic Acid ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Stromal Cells ◽  
Cell Tumor

scholarly journals The efficiency of Zoledronic acid loaded liposomal nanoparticles on breast cancer: an in vitro study.

2015 ◽  
Vol 5 (4) ◽  
pp. 1586-1590
Author(s):  
Mehri Naseri . ◽  
Azim Akbarzadeh . ◽  
Zahra Saffari . ◽  
Hasan Ebrahimi Shahmabadi .
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
In Vitro Study ◽  
Vitro Study ◽  
Liposomal Nanoparticles

scholarly journals Functions of Exogenous RUNX2 in Giant Cell Tumor of Bone In Vitro

2020 ◽  
Vol 12 (2) ◽  
pp. 668-678 ◽  
Author(s):  
Yuan‐han Jin ◽  
Jing Zhang ◽  
Hao Zhu ◽  
Gen‐tao Fan ◽  
Guang‐xin Zhou
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Cell Tumor

scholarly journals New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFRβ Signaling

Cancers ◽  
2021 ◽  
Vol 13 (14) ◽  
pp. 3543
Author(s):  
Michal Mahdal ◽  
Jakub Neradil ◽  
Peter Mudry ◽  
Silvia Paukovcekova ◽  
Iva Staniczkova Zambo ◽  
...  
Keyword(s):  
Growth Factor ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Stromal Cells ◽  
Growth Factor Receptor ◽  
Metastatic Potential ◽  
Giant Cells ◽  
Cell Tumor ◽  
Primary Bone Tumor

Giant-cell tumor of bone (GCTB) is an intermediate type of primary bone tumor characterized by locally aggressive growth with metastatic potential. The aim of this study was to identify new druggable targets among the cell signaling molecules involved in GCTB tumorigenesis. Profiles of activated signaling proteins in fresh-frozen tumor samples and tumor-derived cell lines were determined using phosphoprotein arrays. Analysis of the obtained data revealed epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor beta (PDGFRβ) as potential targets, but only the PDGFR inhibitor sunitinib caused a considerable decrease in stromal cell viability in vitro. Furthermore, in the case of a 17-year-old patient suffering from GCTB, we showed that the addition of sunitinib to the standard treatment of GCTB with the monoclonal antibody denosumab resulted in the complete depletion of multinucleated giant cells and mononuclear stromal cells in the tumor tissue. To summarize, the obtained data showed that a specific receptor tyrosine kinase (RTK) signaling pattern is activated in GCTB cells and plays an important role in the regulation of cell proliferation. Thus, activated RTKs and their downstream signaling pathways represent useful targets for precision treatment with low-molecular-weight inhibitors or with other types of modern biological therapy.

scholarly journals Adjuvant Zoledronic Acid in High‐Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial

2019 ◽  
Vol 24 (7) ◽  
pp. 889 ◽  
Author(s):  
Astrid Lipplaa ◽  
Judith R. Kroep ◽  
Lizz van der Heijden ◽  
Paul C. Jutte ◽  
Pancras C.W. Hogendoorn ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
High Risk ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Cell Tumor ◽  
Randomized Phase Ii
Sign in / Sign up

Export Citation Format

Share Document